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Introduction
Abnormal lipid metabolism is often present in patients
with type 2 diabetes.1,2 Furthermore, abnormality in
the level of each of the major lipids has been inde-
pendently associated with increased risk of cardiovas-
cular disease.2 The American Diabetes Association
currently recommends measurement of plasma lipid
levels annually for type 2 diabetes patients who are not
being treated with lipid-lowering agents.3 However, 
in our clinical practice, dyslipidemia has been observed
more frequently in certain subgroups of diabetic
patients, who would likely benefit from more intensive
monitoring of plasma lipid levels. If we could predict
from certain easily measurable parameters who is most
likely to develop dyslipidemia, then it would allow us to
target these at-risk groups for intensive lipid monitoring.
Plasma lipid concentrations are related to several
anthropometric indices,4–9 including waist circumfer-
ence, waist-to-hip ratio (WHR), body mass index
(BMI), and even skinfold thickness. Plasma lipids are
also influenced by cigarette smoking, alcohol consump-
tion, and physical activity. However, these associations
have not been thoroughly examined in patients with
type 2 diabetes. We therefore conducted this cross-
sectional study to search for patient characteristics
that might best predict higher plasma lipid concen-
trations. We also attempted to characterize patients
who meet the criteria for pharmacologic treatment 
of dyslipidemia according to the guidelines of the
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Bureau of National Health Insurance (BNHI) in
Taiwan.10
Methods
We conducted a cross-sectional survey of patients with
type 2 diabetes who were enrolled in the diabetes case
management program in Changhua Christian Hospital
during the period from April 2002 to May 2004. The
diagnosis of type 2 diabetes was based on the criteria
established by the American Diabetes Association
(ADA). Patients who had been taking antihypertensive
medication, lipid-lowering agents, or oral antidiabetic
agents likely to affect plasma lipid levels11 (thiazolidine-
diones, metformin, alpha-glucosidase inhibitors) were
excluded. Information pertaining to prior medication,
duration of diabetes since diagnosis, and lifestyle factors
(cigarette and alcohol use) was obtained through patient
interview or review of medical records at the time of
enrollment into the diabetes management program.
Blood pressure was measured during clinic visits
using an automated sphygmomanometer, after patients
had remained in a sitting position for at least 10 min-
utes. Hypertension was defined as systolic blood pres-
sure (SBP) ≥ 130 mmHg and/or diastolic blood
pressure (DBP) ≥ 80 mmHg.12 Height was measured
to the nearest centimeter. BMI was calculated as
weight (kg) divided by height squared (m2). Waist
circumference was measured with the measuring tape
positioned midway between the lowest rib and the
iliac crest after the patient had exhaled normally.13 Hip
circumference was measured at the level of the sym-
physis pubis and the great gluteal protuberance.14
Obesity was defined as BMI ≥ 27,15 and abdominal
obesity was defined as WHR ≥ 0.9 for men and ≥ 0.85
for women.16 Eligibility for pharmacologic treatment
of diabetic dyslipidemia was determined using the crite-
ria established by the BNHI,10 which include: (1) total
cholesterol (TC) ≥ 200 mg/dL, or (2) low-density
lipoprotein cholesterol (LDL-C) ≥ 130 mg/dL, or
(3) triglyceride (TG) ≥ 200 mg/dL while either the
high-density lipoprotein cholesterol (HDL-C) level is
< 40 mg/dL or the TC/HDL-C ratio is > 5.
Blood samples were collected in the morning after
an 8- to 12-hour fast. Levels of fasting blood glucose
(FBS), glycosylated hemoglobin A1C (HbA1C), TC,
HDL-C, LDL-C, and TG were determined in the
hospital laboratory using standard methods.
Statistical analysis, including Student’s t test, mul-
tiple regression and multiple logistic regression tests,
was performed with SPSS version 10.0 (SPSS Inc.,
Chicago, IL, USA). A p value < 0.05 was considered
statistically significant.
Results
In total, 408 subjects were included in this study. The
mean age was 55.8 ± 13.9 years. There were 223 men
(54.7%) and 185 (45.3%) women. The means and
standard deviations of anthropometric indices and other
attributes are shown in Table 1. The mean levels of 
TC, LDL-C, TG and HDL-C were 181.4 mg/dL,
Table 1. Anthropometric indices, physical factors, and lipid profiles by sex*
Baseline Total (n = 408) Male (n = 223) Female (n = 185) p
Age (yr) 55.8 ± 13.9 54.1 ± 13.7 58.0 ± 13.8 0.0046
DM duration (yr) 5.7 ± 6.8 5.6 ± 6.8 5.9 ± 6.7 NS
Drinking (yes) 19.4% (n = 79) 31.4% (n = 70) 4.9% (n = 9) < 0.0001
Smoking (yes) 5.9% (n = 24) 8.5% (n = 19) 2.7% (n = 5) 0.0129
BMI 23.9 ± 3.4 23.8 ± 3.2 23.9 ± 3.8 NS
WHR 0.901 ± 0.069 0.913 ± 0.067 0.887 ± 0.069 0.0001
SBP (mmHg) 128.6 ± 18.3 127.0 ± 16.0 130.6 ± 20.6 0.0484
DBP (mmHg) 77.1 ± 10.5 78.0 ± 9.9 76.1 ± 11.2 NS
FBS (mg/dL) 159.0 ± 65.1 156.8 ± 58.8 161.5 ± 72.1 NS
HbA1C (%) 8.39 ± 2.32 8.44 ± 2.40 8.32 ± 2.24 NS
TC (mg/dL) 181.4 ± 39.0 174.5 ± 40.0 189.6 ± 36.1 < 0.0001
TG (mg/dL) 132.0 ± 89.6 137.6 ± 102.2 125.3 ± 71.4 NS
HDL-C (mg/dL) 50.0 ± 13.7 46.3 ± 12.7 54.4 ± 13.6 < 0.0001
LDL-C (mg/dL) 104.8 ± 29.7 101.4 ± 30.2 109.0 ± 28.7 0.0104
*Data are presented as mean ± SD. DM = diabetes mellitus; BMI = body mass index; WHR = waist-to-hip ratio; SBP = systolic blood pressure; DBP = diastolic
blood pressure; FBS = fasting blood glucose; HbA1C = glycosylated hemoglobin A1C; TC = total cholesterol; TG = triglyceride; HDL-C = high-density lipoprotein
cholesterol; LDL-C = low-density lipoprotein cholesterol; NS = not significant.
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104.8 mg/dL, 132.0 mg/dL and 50.0 mg/dL, res-
pectively. Plasma lipid levels other than TG were sig-
nificantly higher in women than in men. Men were
significantly younger and had lower SBP than women.
There were no differences in FBS, HbA1C and BMI
between men and women.
Table 2 shows the correlation between each of the
measured lipids and various nonlaboratory attributes.
Lower plasma concentrations of TC were associated
with the male sex and nondrinkers. Nondrinkers also
had lower TG levels. Plasma HDL-C had negative
correlation, while plasma TG had positive correlation,
with BMI and WHR. Table 3 shows the results of
multiple regression analysis after controlling for age,
the duration of diabetes since diagnosis, cigarette
smoking, alcohol consumption, BMI, WHR, SBP and
DBP in both genders. Among men, plasma TG level
was positively correlated with WHR and alcohol 
consumption, whereas HDL-C level was negatively
correlated with age and BMI, all with statistical signi-
ficance. Among women, plasma TG level was posi-
tively correlated with WHR and the duration of
diabetes since diagnosis, while HDL-C level was neg-
atively correlated with WHR and BMI, all with stat-
istical significance. In both men and women, no
significant correlation with any factor was found for
both TC and LDL-C levels.
Factors that predict eligibility for pharmacologic
treatment of dyslipidemia are shown in Table 4 for
men and Table 5 for women. Diabetic men who were
obese (BMI ≥ 27) or who were alcohol drinkers were
more likely to require pharmacologic treatment for
dyslipidemia than the nonobese and nonalcohol
drinkers (odds ratio [OR], 3.5–4.2). For diabetic
women, the OR for requiring dyslipidemia treatment
increased about 1.2-fold with each 1-year increase in
the duration of diabetes. Overall, 29.4% of patients
met the criteria (23.3% in men, 36.2% in women) for
pharmacologic treatment of dyslipidemia.
Table 2. Correlation of lipid levels with anthropometric indices,
sex, and lifestyle
Dependent Explanatory 
Estimate p
variable variable
Total cholesterol Male sex −18.18 < 0.001
Nondrinker −14.41 0.081
LDL-C Male sex −7.77 0.017
HDL-C Male sex −7.41 < 0.001
BMI −0.94 < 0.001
WHR −31.50 0.001
TG Nondrinker −67.51 < 0.001
BMI 1.35 0.059
WHR 260.48 < 0.001
LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein
cholesterol; BMI = body mass index; WHR = waist-to-hip ratio; TG = triglyceride.
Table 3. Multiple regression analysis of relationship between anthropometric indices, physical factors, and lipid concentrations in 
men and women
Dependent Men Women
variable Explanatory variable Coefficient p Explanatory variable Coefficient p
Cholesterol — — — — — —
TG No drinking −66.80 0.005 DM duration 2.04 0.012
WHR 29.08 0.008 WHR 22.38 0.005
LDL-C — — — — — —
HDL-C Age −0.22 0.001 BMI −0.70 0.012
BMI −1.31 < 0.001 WHR −4.54 0.003
TG = triglyceride; DM = diabetes mellitus; WHR = waist-to-hip ratio × 10; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol;
BMI = body mass index.
Table 4. Factors predicting eligibility for pharmacologic treatment of dyslipidemia in male diabetic patients*†
Guide of treatment n (%) Factor OR 95% CI
LDL-C ≥ 130 mg/dL 28 (12.26) Alcohol use 3.472‡ 1.174–10.309
TC ≥ 200 mg/dL 39 (17.49) Alcohol use 3.922‡ 1.420–10.870
TG ≥ 200 mg/dL and TC/HDL-C > 5 or 20 (8.97) BMI ≥ 27 4.238‡ 1.471–12.207
HDL-C < 40 mg/dL
*Fulfilling any of the three criteria: n = 52 (23.32%); †factors are alcohol use, smoking, systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥
80 mmHg, waist-to-hip ratio ≥ 0.9, body mass index ≥ 27; ‡p < 0.05. OR = odds ratio; CI = confidence interval; LDL-C = low-density lipoprotein cholesterol; 
TC = total cholesterol; TG = triglyceride; HDL-C = high-density lipoprotein cholesterol; BMI = body mass index.
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Discussion
The patients in this study had lower mean lipid values
than previous studies,9,17 with lower TC, LDL-C and
TG, and higher HDL-C levels. Besides ethnicity, dif-
ferences in anthropometric indices, blood pressure, and
lifestyle factors might account for this finding. In this
study, diabetic women had higher serum cholesterol
but similar TG level compared with diabetic men.
Previous studies also had the same finding.17,18 While
the higher HDL-C level among women might be
attributed to gender difference alone,4,5 the higher TC
and LDL-C levels could also be related to the older
mean age in the female group, since TC and LDL-C
are positively correlated with age4,7 and SBP.19,20
Although men did not have higher plasma TG levels in
this study, it might be accounted for by their younger
age compared to women.21
Plasma lipid concentrations might be influenced by
several factors. HDL-C is negatively correlated with
WHR7 and BMI,4,8 and TG is positively correlated with
WHR7 and alcohol consumption.6 TC is positively
associated with alcohol consumption.6 These associa-
tions were also observed in this study. Because there
appeared to be notable gender differences in terms of
these correlations, additional analyses were done sepa-
rately for each gender. After separating the genders,
there was no longer any correlation for TC and LDL-C
levels with any of the factors we investigated. This partly
concurs with another report in which LDL-C was not
related to any of the investigated factors, including age,
gender, glycemia, obesity, and smoking, whereas TC
was related to age and smoking only.4,5 Since the mag-
nitude and strength of the associations between anthro-
pometric measures and serum lipids tend to be greater
among younger subjects,6,22 the older mean age of our
patients might be responsible for weakening these asso-
ciations. With regard to TG level, because of the low
prevalence of female alcohol drinkers in our study
(4.9%) and in the Taiwanese population as a whole, it is
not surprising that the correlation between TG level
and alcohol consumption was observed only among
men. Among women, however, TG is significantly asso-
ciated with the duration of diabetes. This association
has seldom received attention,23 but it should nonethe-
less be taken into consideration when treating diabetic
dyslipidemia.
According to the BNHI guidelines in Taiwan,10
treatment with a statin is suggested if TC or LDL-C 
is higher than desired, whereas a fibrate is suggested
for high TG combined with a low HDL-C. We there-
fore conducted a multiple logistic regression analy-
sis with respect to age, duration since diagnosis of 
diabetes, anthropometric indices, blood pressure, and
alcohol and tobacco usage to see which best predicted
eligibility for pharmacologic treatment according to the
BNHI criteria. We found that alcohol consumption
predicted the requirement of treatment with a statin and
obesity (BMI ≥ 27) predicted treatment with a fibrate
in diabetic men. This finding agreed with a study that
showed that BMI (≥27) was the best predictor for
abnormal TG (≥200mg/dL).5 In female patients, the
requirement for fibrate increased along with the dura-
tion of diabetes. The factors predicting need for treat-
ment with antihyperlipid agents can be explained by the
elevated TG levels frequently found among obese
persons or alcohol drinkers. Overall, statin treatment
is more often indicated in these patients than fibrate
treatment.
There were several limitations in this study. The first
was the sampling bias. Patients enrolled in the program
may not be representative of all type 2 diabetes patients.
Second, physical activity was not considered and the
amount of alcohol and tobacco use was not quan-
tified in our study. These 3 lifestyle factors were
reported to be quantitatively correlated with plasma
lipid levels.4,6,7 Third, disorders that predispose to
hyperlipidemia, such as hypothyroidism and nephrotic
syndrome,24 were not excluded in this study, and
thereby might have introduced statistical bias. Fourth,
the variability in the degree of glycemic control was
not taken into consideration in the statistical analysis.
Good glycemic control by itself might lower plasma
cholesterol and TG levels and elevate HDL-C level.7
Table 5. Factors predicting eligibility for pharmacologic treatment of dyslipidemia in female diabetic patients*†
Guide of treatment n (%) Factor OR 95% CI
LDL-C ≥ 130 mg/dL 36 (19.46) — — —
TC ≥ 200 mg/dL 63 (34.05) — — —
TG ≥ 200 mg/dL and TC/HDL-C > 5 or 10 (5.41) Duration of diabetes (>1 yr) 1.181 1.075–1.297‡
HDL-C < 40 mg/dL
*Fulfilling any of the three criteria: n = 52 (23.32%); †factors are alcohol use, smoking, systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥
80 mmHg, waist-to-hip ratio ≥ 0.9, body mass index ≥ 27; ‡p < 0.05. OR = odds ratio; CI = confidence interval; LDL-C = low-density lipoprotein cholesterol; 
TC = total cholesterol; TG = triglyceride; HDL-C = high-density lipoprotein cholesterol.
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Finally, the accuracy of patients’ medication history
was subject to the reliability of the patients.
In conclusion, of the diabetic patients who were
drug-naïve or who were treated with sulfonylureas only,
about 1-third would require pharmacologic treatment
for dyslipidemia. Female patients were apt to have
higher levels of all major lipids. Alcohol consumption,
BMI, WHR, and age were the most important factors
associated with elevated plasma lipid levels in males. In
consequence, men who were obese (BMI ≥ 27) or who
were alcohol drinkers more frequently required lipid-
lowering treatment. In female patients, BMI, WHR,
and the duration of diabetes were more significantly
associated with plasma lipid levels. Requirement for
treatment with lipid-lowering agents increased with
increasing duration of diabetes. For type 2 diabetes
mellitus patients with lipid levels controlled by diet or
sulfonylureas alone, we recommend a more intensive
monitoring of lipid levels if they possess the afore-
mentioned characteristics.
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